{"id":906882,"date":"2025-11-06T10:20:50","date_gmt":"2025-11-06T15:20:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neumora-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update\/"},"modified":"2025-11-06T10:20:50","modified_gmt":"2025-11-06T15:20:50","slug":"neumora-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neumora-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update\/","title":{"rendered":"Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026<\/em>\n <\/p>\n

\n Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026<\/em>\n <\/p>\n

\n On-track to report data from Phase 1b study of NMRA-511 in Alzheimer\u2019s disease agitation around the end of the year<\/em>\n <\/p>\n

\n $40 million in non-dilutive capital drawn from Neumora\u2019s existing facility with K2 HealthVentures<\/em>\n <\/p>\n

\n Strong financial position with $171.5 million in cash, cash equivalents and marketable securities expected to support operations into 2027<\/em>\n <\/p>\n

WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. <\/strong>(Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.<\/p>\n

\u201cOur recent progress reflects the strength of our pipeline and the differentiated approach we\u2019re taking to address some of the most pressing medical challenges of our time,\u201d said Paul L. Berns, chairman and chief executive officer of Neumora. \u201cWe are particularly encouraged by the compelling data we reported last week for NMRA-215, our highly brain-penetrant NLRP3 inhibitor, which demonstrated class-leading weight loss in multiple DIO mouse models. These findings support our plans to move this program into the clinic in early 2026, with human proof of concept data later that year. Additionally, the expansion of our M4 muscarinic receptor PAM franchise with the initiation of a second Phase 1 study underscores our commitment to addressing the unmet needs in schizophrenia and other neuropsychiatric disorders. With continued progress in our KOASTAL Phase 3 program for navacaprant in MDD and the upcoming data readout for NMRA-511 in Alzheimer\u2019s disease agitation, we remain focused on executing our strategy and delivering meaningful innovation for patients.\u201d<\/p>\n

\n KEY BUSINESS UPDATES<\/strong>\n <\/p>\n

Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company\u2019s balance sheet, further strengthens its financial position.<\/p>\n

\n KEY PIPELINE HIGHLIGHTS <\/strong>\n <\/p>\n

\n
\n NMRA-215: Announced Class-Leading DIO Data from NLRP3 Inhibitor Program <\/u>
\n <\/strong>
\n
In October 2025, Neumora announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. Neumora expects to initiate a clinical program with NMRA-215 in the first quarter of 2026, with 12-week human proof of concept data expected in 2026.<\/p>\n

\n
\n M4 Positive Allosteric Modulator (PAM) Franchise: Initiated Second M4 Clinical Study <\/u>
\n <\/strong>
\n
The company is advancing Phase 1 clinical studies for NMRA-861 and NMRA-898, its potentially best-in-class M4 muscarinic receptor positive allosteric modulators (PAMs). The Company expects to provide a comprehensive franchise update in mid-2026.<\/p>\n

\n
\n NMRA-511: On Track to Report Data from Phase 1b Signal-seeking Study in Alzheimer\u2019s Disease (AD) Agitation Around Year-End<\/u>
\n <\/strong>
\n
Neumora is on track to report data from a Phase 1b signal-seeking study evaluating NMRA-511 as a treatment for AD agitation around the end of 2025.<\/p>\n

\n
\n Navacaprant: Enrollment Ongoing in Phase 3 KOASTAL Program; Topline Data Expected in 1H 2026 <\/u>
\n <\/strong>
\n
The Company is on track to report topline data with navacaprant in MDD from KOASTAL-3 in the first quarter of 2026 and KOASTAL-2 in the second quarter of 2026.<\/p>\n

\n THIRD QUARTER 2025 FINANCIAL RESULTS<\/strong>\n <\/p>\n